VRAX
Virax Biolabs Group Ltd
Company Overview
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
SectorHealthcare
IndustryBiotechnology
Market Cap$1.6M
Last DividendNone
Employees26
CEOJames Foster
Websitehttps://viraxbiolabs.com
Valuation
Current Price$1.22
Fair Value?$000.00
Valuation?No valuation
Current PE ?N/Aⓘ
Hist. PE ?N/Aⓘ
EPS (TTM) ?-40.5
Forward EPS Growth ?—
Historical Growth ?34.50%
Equity, FCF, Long Term Debt, Net Profit, and Shares Outstanding history charts are available on the Pro plan for just $9.99/month.Sign in to unlock Pro
Price?
EPS?
Revenue?
Equity?
ProAvailable on the Pro plan
Free Cash Flow?
ProAvailable on the Pro plan
Long Term Debt?
ProAvailable on the Pro plan
Net Profit?
ProAvailable on the Pro plan
Shares Outstanding?
ProAvailable on the Pro plan
Last updated: 10/23/2026, 11:10:13 PM